Mid
R
RVMDAI Stock Diagnostic Report
Revolution Medicines updates 2026 GAAP operating expenses to $2.1B-$2.2B while preparing potential daraxonrasib launch
Revolution Medicines announced that it expects to reach a turning point in 2026 through significant results from RASolute 302 and an expanded FDA approval program.
View Source Article ↗AI CATALYST SCORE78 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time